ArQule: ARQ 531-101 Ph1 ARQ 531 R/R Hematologic Malignancies
What is the Purpose of this Study?
If you choose to join this study, you will:
- Give samples of your blood
- Have assessments of your vital signs
- Give urine samples
- Get the study drug, ARQ 531, taken by mouth for one week
- Give samples of your blood
- Have assessments of your vital signs
- Give urine samples
- Get the study drug, ARQ 531, taken by mouth for one week
What is the Condition Being Studied?
Relapsed or Refractory Hematologic Malignancies
Who Can Participate in this Study?
Adults who:
- Have good organ function
- Have a platelet count greater than 50,000/microliters
- Have a creatinine clearance of greater than 60 mL/min
- Have hemoglobin (Hgb) greater than 8.0 g/dL and stable for greater than 1 week
Age Group
Adults
Participating Institutions
What is Involved?
We are doing this study to find out what is the best dose of the study drug (ARQ 531) to use in patients with hematologic malignancies.
Study Details
Full Title
A Phase 1 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies
Principal Investigator
Protocol Number
IRB:
PRO00101876
NCT:
NCT03162536
ClinicalTrials.gov
View on ClinicalTrials.gov